A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

NCT07243171 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and tolerability of oral ecnoglutide tablets in Chinese adults who are overweight or have obesity.

Status Recruiting Currently enrolling participants.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 84 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2025-11 · est. completion 2026-11

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07243171 ↗

Description as written by the study sponsor.

The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

Treatments tested

ecnoglutide tablets Drug

oral tablets
placebo with matching dosage Drug

oral tablets

Main thing measured	The incidence and severity of adverse events
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	Overweight and/or Obesity, Weight Management
GLP-1 drugs	ecnoglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07243171 ↗